Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Petros

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Clinical Pharmacokinetics|May 1, 1997
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerationsS C Piscitelli, W G Reiss, W D Figg, et al.
Archives of Pathology & Laboratory Medicine|August 1, 1995
Artifactual hypoglycemia associated with hematopoietic cytokinesJ R Astles, W P Petros, W P Peters, et al.
Therapeutic Drug Monitoring|April 29, 1998
New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal diseaseP F Smith, W P Petros, M P Soucie, et al.
Bone Marrow Transplantation|February 1, 1995
Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicityT Murase, M S Anscher, W P Petros, et al.
The New England Journal of Medicine|June 3, 1993
Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancerM S Anscher, W P Peters, H Reisenbichler, et al.
American Journal of Respiratory and Critical Care Medicine|February 26, 1998
Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancerS W Wilczynski, J J Erasmus, W P Petros, et al.
Experimental Hematology|July 1, 1994
Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantationW P Petros, J Rabinowitz, A R Stuart, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in childrenW E Evans, M V Relling, W P Petros, et al.
Pharmacotherapy|August 6, 1998
Effect of plasma TNF-alpha on filgrastim-stimulated hematopoiesis in mice and humansW P Petros, J Rabinowitz, J P Gibbs, et al.
Clinical Pharmacology and Therapeutics|September 1, 1991
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjectsM V Relling, J Cherrie, M J Schell, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Clinical Pharmacokinetics|May 1, 1997
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerationsS C Piscitelli, W G Reiss, W D Figg, et al.
Archives of Pathology & Laboratory Medicine|August 1, 1995
Artifactual hypoglycemia associated with hematopoietic cytokinesJ R Astles, W P Petros, W P Peters, et al.
Therapeutic Drug Monitoring|April 29, 1998
New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal diseaseP F Smith, W P Petros, M P Soucie, et al.
Bone Marrow Transplantation|February 1, 1995
Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicityT Murase, M S Anscher, W P Petros, et al.
The New England Journal of Medicine|June 3, 1993
Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancerM S Anscher, W P Peters, H Reisenbichler, et al.
American Journal of Respiratory and Critical Care Medicine|February 26, 1998
Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancerS W Wilczynski, J J Erasmus, W P Petros, et al.
Experimental Hematology|July 1, 1994
Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantationW P Petros, J Rabinowitz, A R Stuart, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in childrenW E Evans, M V Relling, W P Petros, et al.
Pharmacotherapy|August 6, 1998
Effect of plasma TNF-alpha on filgrastim-stimulated hematopoiesis in mice and humansW P Petros, J Rabinowitz, J P Gibbs, et al.
Clinical Pharmacology and Therapeutics|September 1, 1991
Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjectsM V Relling, J Cherrie, M J Schell, et al.
Pageof 5